无锡先导智能装备股份有限公司WUXI LEAD INTELLIGENT EQUIPMENT CO., LTD.00470.HK
2024年收入降28.6%、净利润降84.9%后回升
Such downward trend from 2022 to 2024 was primarily attributable to the weakened performance of our downstream industries, which led to reduced demand for our equipment.
Summary · 第 1 页
Our total revenue decreased by 28.6% from RMB16,483.3 million in 2023 to RMB11,773.4 million in 2024, primarily due to decrease in:
Summary · 第 9 页
Our net profit increased by 97.9% from RMB587.0 million in the nine months ended September 30, 2024 to RMB1,161.3 million in the nine months ended September 30, 2025, primarily due to (i) an increase in revenue and (ii) a change of impairment losses under expected credit loss model from impairment losses of RMB515.7 million to reversal of impairment losses of RMB215.7 million, which was primarily because the lithium battery industry recovered and production normalized, which significantly improved customers’ ability to make payments.
Our net profit decreased by 68.6% from RMB432.0 million in 2022 to RMB135.7 million in 2023, primarily due to (i) the decrease in our revenue by 41.3% from RMB2,786.2 million in 2022 to RMB1,634.3 million in 2023, which was mainly attributable to a decline in the industry in which we operate and in various downstream sectors
Summary · 第 13 页
Our net profit increased by 120.8% from RMB135.7 million in 2023 to RMB299.6 million in 2024, primarily due to the increase in our revenue by 104.6% from RMB1,634.3 million in 2023 to RMB3,343.1 million in 2024
Our net profit decreased significantly from RMB83.5 million in 2022 to RMB29.1 million in 2023, primarily due to (i) the increases in our capital investment and interest expenses in connection with the construction of the DR Congo copper smelting project; (ii) a decrease in our gross profit in 2023 as our DR Congo copper smelting project had yet to achieve economies of scale prior to its commencement of operations in August 2023 and remained in the ramp-up phase throughout the year; and (iii) the impairment loss recognized on the loans granted to an associate, Jiangxi Tungsten Jinxun Resources Africa SAS.
In particular, according to Frost & Sullivan, the overall semiconductor industry were at a downturn phase from 2023, featured by inventory buildup, weakened consumer demand, and falling price across different products.
Financial Information · 第 248 页
The industry cycle has had, and will continue to have, a significant impact on the demand for and pricing of our various types of chips on offer.
Financial Information · 第 248 页
We expect to continue to broaden our product portfolio to enhance our resilience against fluctuations and capture the growth opportunities presented by different end-markets, as cyclical softness in one end market may be partially offset by resilience or growth in others.
We recorded net profit from continuing operations of RMB97.2 million and RMB9.0 million in 2023 and 2024, respectively.
Financial Information · 第 250 页
The net profit decreased primarily due to (1) an increase of RMB34.7 million in sales and marketing expenses, (2) an increase of RMB25.0 million in insurance channel expenses, and (3) an increase in listing expense of RMB12.1 million.
Financial Information · 第 250 页
Our gross profit was RMB325.2 million, RMB391.5 million, RMB361.6 million, RMB175.4 million and RMB213.2 million in 2022, 2023, 2024 and the six months ended June 30, 2024 and 2025, respectively, representing a gross profit margin of 82.6%, 79.9%, 38.3%, 49.4% and 32.5% for the same periods, respectively.
Our profit for the period decreased by 14.4%, from RMB999.4 million in the five months ended May 31, 2024 to RMB855.5 million in the same period of 2025 due to a decrease in gross profit as a result of the increase in market prices of certain key raw materials.
中伟新材料股份有限公司CNGR Advanced Material Co., Ltd.02579.HK
2024年及2025年上半年净利润下滑
Our net profit increased from RMB1,539.4 million in 2022 to RMB2,100.5 million in 2023, which decreased to RMB1,787.8 million in 2024, primarily due to the fluctuation in gross profit as mentioned above.
Summary · 第 16 页
Our gross profit margin decreased from 13.4% in 2023 to 12.0% in 2024, primarily due to the significant increase in revenue contribution from of new energy metal products, which have lower gross profit margin as compared to our new energy battery materials.
Summary · 第 14 页
an increase in other expenses primarily attributable to an increase in exchange losses mainly caused by the fluctuation in exchange rates of US dollar
Our revenue decreased from RMB1,109.8 million for the six months ended June 30, 2024 to RMB1,063.2 million for the six months ended June 30, 2025.
Summary · 第 1 页
Our profit and total comprehensive income decreased from RMB146.0 million for the six months ended June 30, 2024 to RMB120.0 million for the six months ended June 30, 2025.
Summary · 第 2 页
We may record a slight decrease in the profit and total comprehensive income from the year ended December 31, 2024 to the year ending December 31, 2025, mainly due to the increase in our administrative expenses, primarily because we expect to record an increase in professional service fee and an increase in listing expense in connection with the proposed Listing.
Our net profit decreased from RMB31.7 million in 2023 to RMB21.1 million in 2024, primarily because we incurred higher administrative expenses in 2024 in relation to the professional service fees, which was mainly attributable to service fees we paid in relation to the Listing.
Summary · 第 16 页
In the three months ended March 31, 2025, we recorded revenue from CF017 of RMB124.6 million, slightly decreasing from RMB136.8 million from the same period in 2024, primarily due to the less favorable terms of the 2025 VBP Scheme.
Despite the increase in our gross profit from RMB1,017.4 million in 2023 to RMB1,027.3 million in 2024, our profit decrease from RMB387.9 million to RMB328.9 million during the same periods, primarily due to a significant increase in share-based payment expenses and the listing expenses recorded in 2024.
Summary · 第 15 页
As a result of the overall industry slowdown and intensified competition, our average GMV per store decreased from RMB1.6 million in 2023 to RMB1.4 million in 2024, and our average GMV per order decreased from RMB26 to RMB25.
Summary · 第 2 页
In 2024, our same-store GMV decreased by 10.6%, primarily due to the overall industry slowdown and intensified competition in 2024.
Our adjusted net profit (non-IFRS measures) decreased by 51.3% from RMB30.4 million for the six months ended June 30, 2023 to RMB14.8 million for the six months ended June 30, 2024, primarily because our profit from operations decreased by 88.0% from RMB20.9 million for the six months ended June 30, 2023 to RMB2.5 million for the six months ended June 30, 2024.
Summary · 第 9 页
Such decrease in profit from operations was mainly because (i) our revenue had relatively modest growth, which increased by 14.5% from RMB534.0 million for the six months ended June 30, 2023 to RMB611.5 million for the six months ended June 30, 2024, and (ii) our gross profit margin slightly decreased from 32.6% for the six months ended June 30, 2023 to 30.0% for the six months ended June 30, 2024; as compared to (i) the relatively high increase in our selling expenses, which grew by 26.1% from RMB78.2 million for the six months ended June 30, 2023 to RMB98.6 million for the six months ended June 30, 2024, primarily due to the increase in expenses for promotion of our overall brand and offerings among customers, physicians and hospitals, and (ii) the relatively high increase in our research and development costs, which grew by 48.4% from RMB36.4 million for the six months ended June 30, 2023 to RMB54.0 million for the six months ended June 30, 2024, primarily due to the increase in technical and outsourcing service fees in relation to development of AI-based plugins.
Our revenue decreased by 13.9% from RMB1,307.3 million in 2021 to RMB1,125.4 million in 2022, primarily due to a decrease of RMB163.3 million in revenue from sales of goods.
Summary · 第 17 页
Our revenue generated from sales of enoxaparin API decreased by 61.3% from RMB121.8 million in 2021 to RMB47.1 million in 2022, which was mainly due to a geopolitical conflict which affected our sales to a client in Ukraine.
Summary · 第 18 页
Our revenue from oncology and hematology therapeutic areas declined during the Track Record Period primarily because most of our marketed products in these therapeutics areas are biosimilars or generic small molecule drugs subject to the impact of the VBP schemes, which has exerted downward pressure on the prices and sales volume of relevant products during the Track Record Period.
We recorded a net profit of RMB113.9 million, RMB94.5 million and RMB416.3 million in 2021, 2022 and 2023, respectively.
Summary · 第 3 页
For 2021 and 2022, we had 18 same stores, whose sales decreased by 17.6% from RMB1,107.3 million in 2021 to RMB911.9 million in 2022, which was primarily due to the temporary closure of some of our boutiques as a result of the impact of the COVID-19.
Business · 第 198 页
Specifically, in 2022, 16 of the 18 same stores were temporarily closed for a period ranging from three days to 42 days under the COVID-19 pandemic.
Our adjusted net profit (non-IFRS measure) for the year decreased by 34.9% from RMB20.9 million for the year ended 31 December 2021 to RMB13.6 million for the year ended 31 December 2022, mainly as a result of the increase in the research and development expenses, which was attributable to (i) the hiring of new and qualified research and development staff and (ii) the testing fee of RMB5.7 million incurred for testing the performance of edge nodes at the edge computing infrastructure in Shandong Province, and the increase in the administrative expenses attributable to the increase of salaries and benefits of our administration employees.
Financial Information · 第 354 页
Our adjusted net profit (non-IFRS measure) amounted to RMB20.9 million, RMB13.6 million and RMB23.6 million for the years ended 31 December 2021, 2022 and 2023, respectively.
Revenue decreased by 31.0% from RMB677.7 million in 2021 to RMB467.6 million in 2022, and increased by 5.2% to RMB492.0 million in 2023.
Summary · 第 11 页
Our profit for the year was RMB165.1 million, RMB69.0 million and RMB9.3 million in 2021, 2022 and 2023, respectively.
Summary · 第 2 页
Our profit for the year decreased from 2022 to 2023 primarily because we recorded losses of RMB75.0 million in fair value change of financial liabilities at fair value through profit or loss, in line with the increased valuation of our Company in anticipation of this Offering.
Our net profit decreased by HK$5.2 million or 23.3% from HK$22.3 million for the six months ended 30 September 2022 to HK$17.1 million for the six months ended 30 September 2023 due to the listing expenses incurred for the Listing and Global Offering.
Summary · 第 2 页
Our net profit decreased in the six months ended 30 September 2023 as compared to the same period in 2022, primarily due to the effect of listing expenses in the amount of HK$14.5 million in relation to the Listing and Global Offering.
In view of the above, both our Songjiagou Open-Pit Mine and Songjiagou Underground Mine have suspended mining operations from February to August 2021 and February to November 2021, respectively while our ore processing plant was required to suspend operation from March to August 2021 (except for certain test runs in April and May 2021) for the government authority to carry out safety inspection.
Summary · 第 15 页
In addition, our gold production volume during FY2021 decreased by approximately 414.5 kg or 41.8% as compared to FY2020, which led to the decreases in our revenue of approximately 31.3% and our profit for the year by approximately 48.7% in FY2021 as compared to FY2020.
Summary · 第 15 页
Since we had already terminated substantially all of our mining works subcontractors for the Songjiagou Open-Pit Mine in September 2020 and the Songjiagou Underground Mine in January 2021 and we substantially carried out all the mining works ourselves, there has been no material impact on the introduction of the safety requirements to our business operation and we have complied with such requirements to ensure safety of our mines.
普洱澜沧古茶股份有限公司PU’ER LANCANG ANCIENT TEA CO., LTD.06911.HK
2022年收益及净利润下滑
Our revenue decreased by 17.1% from RMB558.7 million in 2021 to RMB462.9 million in 2022, primarily as a result of COVID-19 recurrences across the country in 2022, which caused disruptions to the operation of our stores in the affected regions.
Summary · 第 10 页
Our net profit increased from RMB123.0 million in 2020 to RMB129.0 million in 2021 and decreased to RMB70.5 million in 2022, mostly in line with the fluctuation of our gross profit in the relevant years.
Summary · 第 11 页
Our gross profit margin decreased from 70.4% in 2020 to 65.9% in 2021, primarily due to more non-fermented Pu’er tea leaf products launched in 2021, which generally have a lower margin than fermented Pu’er tea leaf products.
泛远国际控股集团有限公司FAR International Holdings Group Company Limited02516.HK
往绩期间收入及溢利持续下降
During the Track Record Period, there was a decreasing trend in our revenue.
Summary · 第 3 页
Our profit for FY2021 decreased by approximately RMB15.8 million, or approximately 30.0% from approximately RMB52.7 million for FY2020 to approximately RMB36.9 million for FY2021.
Summary · 第 15 页
Our profit for 6M2023 decreased by approximately RMB2.9 million, or approximately 21.0% from approximately RMB13.8 million for 6M2022 to approximately RMB10.9 million for 6M2023.